Drugs / Intralipid
Intralipid
Trials 36 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04832009 | May 2022 → Aug 2026 overdue | hypertensive disorder | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT03479671 | Jan 2020 → Nov 2024 | type 2 diabetes mellitus | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT02697201 | Jul 2016 → May 2021 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05553405 | Jan 2024 → Jan 2033 | obesity disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 1 | NCT03132779 | May 2017 → Jan 2018 | pregnancy loss, recurrent, 4 | Ahmed Mohamed Bahaa Eldin Ahmed | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04328337 | Dec 2020 → Jun 2026 overdue | obesity disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03374163 | Jan 2015 → Jun 2017 | infertility disorder | King Fahad Medical City | Completed | No outcome recorded |
| Phase 2 | NCT01602250 | Jan 2011 → Aug 2013 | poisoning | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04393103 | Apr 2024 → Jan 2025 | organophosphate poisoning | Amani Hassan Abdel-Wahab | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01540591 | Feb 2012 → Sep 2013 | infertility disorder | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT00989339 | Nov 2009 → Dec 2011 | diabetes mellitus, hypertensive disorder, obesity disorder | Emory University | Withdrawn | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03387579 | Nov 2018 → Mar 2021 | parenteral nutrition-associated cholestasis | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT02357576 | May 2016 → Oct 2017 | cholestasis | University of Michigan | Completed | No outcome recorded |
| Phase 3 | NCT00451646 | Oct 2007 → Oct 2008 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT04274803 | Apr 2020 → May 2021 | antiphospholipid syndrome | Tanta University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03968822 | Jul 2019 → Oct 2026 expected | — | Hospital for Special Surgery, New York | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03857646 | Mar 2019 → Jun 2020 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT02924454 | Sep 2016 → Mar 2017 | hypertensive disorder | Mikkel Bring Christensen | Completed | No outcome recorded |
| Phase 4 | NCT01788540 | Feb 2013 → Aug 2016 | habitual spontaneous abortion | Woman's Health University Hospital, Egypt | Completed | No outcome recorded |
| Phase 4 | NCT01786759 | Oct 2012 → May 2013 | pulmonary immaturity | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01683162 | Jul → Dec 2012 | pulmonary immaturity | Wei Cai | Unknown | No outcome recorded |
| Phase 4 | NCT01679561 | Feb → Aug 2012 | low implantation of placenta | Woman's Health University Hospital, Egypt | Withdrawn | No outcome recorded |
| Phase 4 | NCT00188773 | Jan 2004 → Aug 2007 | metabolic syndrome X | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT06988982 | Jun 2025 → Feb 2026 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT04807634 | Mar → Sep 2021 | hepatic coma | Ain Shams University | Unknown | No outcome recorded |
| — | NCT04558190 | Sep 2020 → Nov 2021 | — | University of Copenhagen | Completed | No outcome recorded |
| — | NCT02517307 | Feb 2016 → Jan 2021 | carnitine palmitoyl transferase II deficiency, myopathic form, long chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium chain acyl-CoA dehydrogenase deficiency, mitochondrial trifunctional protein deficiency +1 | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT02463812 | May 2015 → Apr 2017 | — | University of Alberta | Withdrawn | No outcome recorded |
| — | NCT01520454 | Nov 2011 → Dec 2013 | obesity disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT02406586 | Jul 2009 → Mar 2011 | diabetes mellitus, hypertensive disorder | Emory University | Completed | No outcome recorded |
| — | NCT00786487 | Jan 2009 → Jan 2014 | — | University of Minnesota | Completed | No outcome recorded |
| — | NCT01096446 | Apr 2008 → May 2010 | hyperglycemia, hypertriglyceridemia | OSF Healthcare System | Terminated | No outcome recorded |
| — | NCT01740817 | Jan 2008 → Dec 2013 | diabetes mellitus, obesity disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT00278928 | Jan 2006 → Apr 2007 | hypertriglyceridemia | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| — | NCT00184899 | Aug 2005 → Aug 2006 | metabolic syndrome X, obesity disorder | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00152945 | Apr 2005 → Jul 2008 | — | University Health Network, Toronto | Completed | No outcome recorded |
Also used as a comparator or background therapy in 34 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02512718 Comparator | Jun 2016 → May 2023 | disease related to hematopoietic stem cell transplant | Alexandra N. Carey | Completed | No outcome recorded |
| Phase 1 | NCT02240498 Background | Sep 2014 → Sep 2023 | abscess | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT00512629 Comparator | Jul 2007 → Dec 2011 | parenteral nutrition-associated cholestasis | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02865785 Comparator | Jul 2016 → Jul 2017 | infertility disorder | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02365285 Background | Mar 2015 → Oct 2017 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07179003 Background | Apr 2026 → Mar 2031 expected | breast abscess | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04584983 Comparator | Feb 2021 → Mar 2024 overdue | bilirubin encephalopathy | The University of Texas Health Science Center, Houston | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03127345 Comparator | Sep 2019 → Sep 2023 | esophageal atresia | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01096771 Comparator | Jun 2010 → Nov 2012 | acute respiratory distress syndrome | Methodist Research Institute, Indianapolis | Terminated | No outcome recorded |
| Phase 2 | NCT00793195 Comparator | Jan 2009 → Sep 2011 | chronic intestinal failure, intestinal motility disease, short bowel syndrome | The Hospital for Sick Children | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02807727 Comparator | Jan 2017 → Jun 2018 | — | Nkanyiso Hadebe | Unknown | No outcome recorded |
| Phase 2/3 | NCT00672854 Comparator | Nov 2008 → Dec 2010 | — | Emory University | Completed | No outcome recorded |
| Phase 2/3 | NCT02185729 Comparator | Jun 2008 → Mar 2012 | metabolic disease | Emory University | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04466618 Comparator | Apr 2021 → Dec 2022 | type 2 diabetes mellitus | Adrian Vella | Completed | No outcome recorded |
| Phase 3 | NCT02579265 Comparator | Dec 2015 → Apr 2020 | — | Fresenius Kabi | Terminated | No outcome recorded |
| Phase 3 | NCT02663453 Comparator | Dec 2013 → Dec 2015 | cholestasis | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT01916798 Comparator | May 2013 → Jan 2015 | infertility disorder | Cairo University | Terminated | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT04555044 Comparator | Jan 2021 → Oct 2022 | metabolic disease | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04806425 Comparator | Oct 2020 → Feb 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03563222 Comparator | Dec 2019 → Nov 2020 | protein-energy malnutrition | Fresenius Kabi | Terminated | No outcome recorded |
| Phase 4 | NCT03054948 Comparator | Feb 2017 → Mar 2018 | short bowel syndrome | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 4 | NCT02476994 Comparator | May 2015 → Oct 2016 | metabolic disease | Baxter Healthcare Corporation | Terminated | No outcome recorded |
| Phase 4 | NCT02349594 Comparator | Jan 2014 → May 2015 | Crohn disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01943409 Comparator | Jul 2013 → Dec 2019 | cancer, ileus, protein-energy malnutrition | Johane Allard | Completed | No outcome recorded |
| Phase 4 | NCT02487940 Comparator | Oct 2012 → Apr 2015 | infertility disorder | Dar El Teb Institute | Completed | No outcome recorded |
| Phase 4 | NCT01585935 Comparator | Jun 2012 → Jun 2015 | cholestasis, neurodevelopmental disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01373918 Comparator | Dec 2010 → Jul 2014 | cholestasis | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 4 | NCT01054989 Comparator | Mar 2009 → Sep 2011 | — | German Diabetes Center | Completed | No outcome recorded |
| Phase 4 | NCT01115179 Comparator | Mar → Dec 2005 | — | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT00738023 Comparator | Mar 2004 → Dec 2009 | hypertensive disorder, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT02653092 Comparator | Jun 2016 → Dec 2023 overdue | hyperinsulinism, hypogonadotropic hypogonadism, infertility disorder, obesity disorder | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| — | NCT01284049 Comparator | Nov 2011 → Apr 2015 | liver disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00589888 Comparator | Aug 2006 → Apr 2008 | hypertensive disorder | Emory University | Completed | No outcome recorded |
| — | NCT00753142 Comparator | Mar 2004 → Dec 2009 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 70 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INTRALIPID | “We conducted an interventional trial using either a 6-h lipid (20% Intralipid at 90 ml/h) or glycerol (2.25 g/100 ml at 90 ml/h) infusion along with a concurrent...” PMID 22639293 ↗ May 201267“Sixty (30/30) premature neonates (age 3-7 days, gestational age ≤ 34 weeks, birth weights 1000-2500 g) received parenteral nutrition (PN) with either SMOFlipid 20% (study...” PMID 20531018 ↗ Oct 2010 “The purpose of the study is to test whether INTRALIPID administered at reperfusion can limit myocardial reperfusion injury as measured by cTnI release in patients undergoing...” NCT02807727 ↗ “The cavity will then be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the...” NCT02240498 ↗ “The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.” NCT00989339 ↗ “For the experimental group, Intralipid will be increased by 0.5 grams/kg/day until a goal rate of 3 grams/kg/day is achieved.” NCT01096446 ↗ “This lipid emulsion will be either Intralipid or Nutrilipid.” NCT07179003 ↗ “In most cases standard therapy will be IntraLipid.” NCT03054948 ↗ “Fat infusion (Intralipid) over 6 hours” NCT01054989 ↗ |
| Known as | INTRALIPID (soy bean oil) | “INTRALIPID (soy bean oil)” NCT01585935 ↗ |
| Known as | Intralipid 20% | “Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.” NCT01284049 ↗ |
| Known as | Intralipid 20% (20% i.v. fat emulsion) | “Intralipid® 20% (20% i.v. fat emulsion)” NCT03563222 ↗ |
| Known as | Intralipid 20% (a 20% intravenous fat emulsion) | “Intralipid® 20% (a 20% intravenous fat emulsion)” NCT02579265 ↗ |
| Known as | Intravenous Lipid Emulsion | “Intravenous Lipid Emulsion (Intralipid 20%)” NCT04807634 ↗ |
| Known as | SOLE | “Soybean oil lipid emulsion (SOLE) is the standard lipid emulsion used in PN.” NCT02512718 ↗ |
| Known as | Soybean oil lipid emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02512718 ↗ |
| Modality | Other / unclassified | “intralipid (a synthetic triglyceride emulsion that provides a source of fatty acids)” NCT00152945 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00152945 ↗ |